Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Papadopoulos

Showing results (191-200 of 288) with videos related to

Pageof 29
Sort By:
Advances in Therapy|March 26, 2021
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic AnalysisAnne J Paccaly, Michael R Migden, Kyriakos P Papadopoulos, et al.
International Journal of Cancer|March 12, 2021
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I studyNizar M Tannir, Kyriakos P Papadopoulos, Deborah J Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumorsA W Tolcher, K P Papadopoulos, A Patnaik, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumorsAung Naing, Joseph P Eder, Sarina A Piha-Paul, et al.
The Oncologist|May 11, 2021
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Wael Harb, Cody J Peer, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2013
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancerAmita Patnaik, Kyriakos P Papadopoulos, Anthony W Tolcher, et al.
Journal of Hematotherapy|February 1, 1997
Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell supportK P Papadopoulos, J Ayello, S Tugulea, et al.
Current Vascular Pharmacology|January 4, 2018
Aortic Stenosis, Aortic Regurgitation and Arterial HypertensionV Katsi, G Georgiopoulos, D Oikonomou, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|March 31, 2018
The impact of financial crisis on coronary artery disease burden in GreeceElias A Sanidas, Theodoros G Papaioannou, Dimitrios P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Larry Gluck, Lainie P Martin, et al.
Pageof 29

Showing results (191-200 of 288) with videos related to

Sort By:
Pageof 29
Advances in Therapy|March 26, 2021
Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic AnalysisAnne J Paccaly, Michael R Migden, Kyriakos P Papadopoulos, et al.
International Journal of Cancer|March 12, 2021
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I studyNizar M Tannir, Kyriakos P Papadopoulos, Deborah J Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 10, 2015
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumorsA W Tolcher, K P Papadopoulos, A Patnaik, et al.
Journal for Immunotherapy of Cancer|August 27, 2020
Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumorsAung Naing, Joseph P Eder, Sarina A Piha-Paul, et al.
The Oncologist|May 11, 2021
First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Wael Harb, Cody J Peer, et al.
Cancer Chemotherapy and Pharmacology|April 2, 2013
Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancerAmita Patnaik, Kyriakos P Papadopoulos, Anthony W Tolcher, et al.
Journal of Hematotherapy|February 1, 1997
Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell supportK P Papadopoulos, J Ayello, S Tugulea, et al.
Current Vascular Pharmacology|January 4, 2018
Aortic Stenosis, Aortic Regurgitation and Arterial HypertensionV Katsi, G Georgiopoulos, D Oikonomou, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|March 31, 2018
The impact of financial crisis on coronary artery disease burden in GreeceElias A Sanidas, Theodoros G Papaioannou, Dimitrios P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2017
First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Larry Gluck, Lainie P Martin, et al.
Pageof 29